A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients With Uncontrolled Hypertension
Latest Information Update: 03 Aug 2023
At a glance
- Drugs Baxdrostat (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms HALO
- Sponsors CinCor Pharma
- 28 Nov 2022 According to a CinCor Pharma media release, HALO in combination with BrigHtn informs the dose and study populations anticipated to be recruited into Phase 3 trials pending confirmation by FDA at planned end of Phase 2 meeting in January 2023.
- 28 Nov 2022 According to a CinCor Pharma media release, the company will hold a conference call and live webcast today to provide an update on the trial.
- 28 Nov 2022 Primary endpoint has not been met. (Change from baseline in mean seated systolic BP (SBP)), according to a CinCor Pharma media release.